Delivery Order SPE2DB22D2007-SPE2DB25FJ3EV
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 25, 2025, for the supply of Benlysta 400 mg vials, with a ceiling value of $13,678.56 and firm fixed pricing. The contract is non-set-aside and competitively awarded, with an ultimate completion date of August 15, 2025. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 22, 2025, with an ultimate completion date of August 12, 2025. This is a firm fixed-price, non-set-aside contract performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00...
- The Defense Logistics Agency awarded a $3,076.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/ml syringes, with an ultimate completion date of August 8, 2025. The contract, issued on July 18, 2025, carries no set-aside designation and represents a competitively awarded procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Benlysta 200 mg/ml syringes valued at $3,076.40. This is a firm fixed price delivery order with an ultimate completion date of August 14, 2025, and represents a non-competitive set-aside. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This competitive award, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by August 14, 2025, with fulfillment performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic medication used primarily in the treatment of systemic lupus...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of Benlysta 120 mg vials. The contract, valued at $2,275.20, has an ultimate completion date of April 17, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order and does not have any major subcontractors mentioned. This delivery order is issued under a larger indefinite delivery contract...
- The Defense Logistics Agency awarded a $9,229.20 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml syringes, with an ultimate completion date of August 12, 2025. This non-competitive delivery order utilizes firm fixed pricing and is being performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta is a biologic medication used to treat systemic lupus erythematosus and lupus nephritis, representing a specialized pharmaceutical product within the federal...
- The Defense Logistics Agency awarded a $6,165.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units. The contract, issued on July 22, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of 400 mg vials of the pharmaceutical product BENLYSTA. The delivery order, valued at $1,259.50, has a completion date of March 19, 2024 and was awarded on February 27, 2024. AmerisourceBergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued up to $999,999,999.00, through December 31, 2025, which serves...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3EVDelivery Order
The Defense Logistics Agency (DLA) awarded a $10,518.48 delivery order to AmerisourceBergen Drug Corp for the supply of Benlysta 400 mg vials, with an ultimate completion date of August 12, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor for military and veteran healthcare systems. The delivery order is being performed at the vendor's Conshohocken location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products, specialty medications, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. Benlysta (belimumab) is a monoclonal antibody used in treating systemic lupus erythematosus, representing the specialized pharmaceutical commodities typical of this strategic contract vehicle that serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 7/22/25 |